Why did UnitedHealth raise its 2026 guidance?

Management attributed the raise to performance year-to-date and an improved outlook for the remainder of 2026. Full-year adjusted EPS guidance moved to $19.50–$20.00 from $17.75 in January, and reported operating earnings guidance rose to over $25.45 billion from over $24.00 billion. The medical care ratio guidance improved to 88.1% (±25 bps) from 88.8% (±50 bps).

How much of the earnings improvement came from one-time or non-operating items?

Some of the quarter's strength came from reserve development. The company recorded $860 million of net favorable prior-period medical reserve development, mostly related to 2026 dates of service. Adjusted results exclude items such as South American divestiture losses ($61 million in Q2) and loss contract reserve changes. Investors should evaluate how much of the margin improvement is sustainable versus reserve timing.

What is happening to UnitedHealth's membership base?

Membership is contracting across several segments. UnitedHealthcare served 48.5 million people, down from 50.1 million a year earlier. Medicare Advantage seniors fell 965,000 since year-end 2025, Community & State declined by 380,000 in the quarter (partly from the Louisiana plan exit), and Employer & Individual fell by 145,000. Optum Health also lost about 700,000 value-based-care patients. Management is prioritizing pricing discipline over volume.

Is the company's cash flow and balance sheet in good shape?

Operating cash flow for the first half was $20.0 billion, and Q2 operating cash flow was $11.1 billion, or 1.9x net income, though this was boosted by timing of a large government payment. The debt-to-capital ratio fell to 41.2% from 44.1% a year earlier but remains above the company's ~40% year-end target. Management expects full-year operating cash flow of about $24 billion and at least $5 billion in share repurchases.

What are the main risks to the updated outlook?

Key risks include medical cost trends that could erode the MCR, continued membership attrition, and government program risks such as Medicare Advantage rate and star ratings changes, risk adjustment audits, and DOJ legal actions. The company also faces rising operating costs from ongoing technology investment and execution risk on value-based care and portfolio divestitures, including the remaining South American operations.

UNH 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed July 16, 2026. Cited figures are marked; the original filing is the authoritative source.

UnitedHealth Group (UNH) reported second quarter 2026 results on July 16, 2026, with revenues of $112.0 billion^a (up modestly from $111.6 billion a year earlier) and earnings from operations of $8.0 billion, versus $5.2 billion in Q2 2025.

Diluted EPS was $6.04^b and adjusted EPS was $6.38, compared with $3.74 and $4.08 a year earlier. The improvement was driven primarily by a medical care ratio of 86.7%, down from 89.4% a year ago, which benefited from pricing discipline, benefit design changes, favorable member mix, and $860 million of net favorable prior-period reserve development. Operating cost ratio rose to 12.7% from 12.3% as the company invested in technology, AI, care delivery, and community programs.

Cash flow from operations was $11.1 billion^c, or 1.9x net income, though management attributed part of this to the timing of a substantial government payment. Management raised full-year 2026 guidance: diluted EPS is now expected at $18.45 to $18.95 and adjusted EPS at $19.50 to $20.00, up from $17.10 and $17.75 in January. The updated outlook assumes a full-year MCR of 88.1% (±25 bps), cash flows from operations of about $24 billion, and share repurchases of at least $5 billion.

Segment trends were mixed: UnitedHealthcare membership fell to 48.5 million (down 525,000 sequentially) with Medicare Advantage seniors down 965,000 since year-end 2025, while UnitedHealthcare operating margin recovered to 4.6% from 2.4%. Optum earnings rose to $4.0 billion^d with a 6.2% margin, though Optum Health revenue fell 5% on roughly 700,000 fewer value-based-care patients.

The filing also highlights a set of affordability and governance commitments, including prior-authorization reductions, a fee-based pharmacy model, a $1 billion commitment to the United Health Foundation, and ACA profit rebates. Investors should note that the guidance raise rests on a strong first half with a reserve release contributing to results, that membership continues to contract, and that the company's debt-to-capital ratio of 41.2% remains above its roughly 40% year-end target.

02—Key points

Key Highlights

Q2 2026 revenue of $112.0B vs. $111.6B a year ago; earnings from operations of $8.0B vs. $5.2B (up ~55%)
Medical care ratio improved to 86.7% from 89.4% year-over-year, including $860M of net favorable prior-period reserve development
Adjusted EPS of $6.38 vs. $4.08 in Q2 2025; GAAP diluted EPS of $6.04 vs. $3.74
Full-year 2026 guidance raised: adjusted EPS to $19.50–$20.00 (from $17.75 floor) and diluted EPS to $18.45–$18.95 (from $17.10)
Operating cost ratio rose to 12.7% from 12.3% due to targeted technology, AI, and community investments
Membership declined: UnitedHealthcare served 48.5M people (down 525K sequentially); Medicare Advantage down 965K since year-end 2025
Operating cash flow of $11.1B in Q2 (1.9x net income) was partly boosted by timing of a substantial government payment; debt-to-capital ratio improved to 41.2%

03—Questions

Frequently Asked Questions

Why did UnitedHealth raise its 2026 guidance?
Management attributed the raise to performance year-to-date and an improved outlook for the remainder of 2026. Full-year adjusted EPS guidance moved to $19.50–$20.00 from $17.75 in January, and reported operating earnings guidance rose to over $25.45 billion from over $24.00 billion. The medical care ratio guidance improved to 88.1% (±25 bps) from 88.8% (±50 bps).
How much of the earnings improvement came from one-time or non-operating items?
Some of the quarter's strength came from reserve development. The company recorded $860 million of net favorable prior-period medical reserve development, mostly related to 2026 dates of service. Adjusted results exclude items such as South American divestiture losses ($61 million in Q2) and loss contract reserve changes. Investors should evaluate how much of the margin improvement is sustainable versus reserve timing.
What is happening to UnitedHealth's membership base?
Membership is contracting across several segments. UnitedHealthcare served 48.5 million people, down from 50.1 million a year earlier. Medicare Advantage seniors fell 965,000 since year-end 2025, Community & State declined by 380,000 in the quarter (partly from the Louisiana plan exit), and Employer & Individual fell by 145,000. Optum Health also lost about 700,000 value-based-care patients. Management is prioritizing pricing discipline over volume.
Is the company's cash flow and balance sheet in good shape?
Operating cash flow for the first half was $20.0 billion, and Q2 operating cash flow was $11.1 billion, or 1.9x net income, though this was boosted by timing of a large government payment. The debt-to-capital ratio fell to 41.2% from 44.1% a year earlier but remains above the company's ~40% year-end target. Management expects full-year operating cash flow of about $24 billion and at least $5 billion in share repurchases.
What are the main risks to the updated outlook?
Key risks include medical cost trends that could erode the MCR, continued membership attrition, and government program risks such as Medicare Advantage rate and star ratings changes, risk adjustment audits, and DOJ legal actions. The company also faces rising operating costs from ongoing technology investment and execution risk on value-based care and portfolio divestitures, including the remaining South American operations.

04—Continue

← View all 8-K filings